Baird Medical Announces Regulatory Milestones in Vietnam and Egypt, Expanding International Reach of Microwave Ablation Technology
Key Highlights
- ➤Vietnam grants Class C registrations for Baird Medical’s MWA needles and generators
- ➤Egypt grants preliminary approval for Baird Medical’s BD-GT Microwave Ablation System
- ➤Baird Medical continues regulatory expansion across Argentina, Vietnam, Indonesia, Pakistan, and Egypt
- ➤FDA-cleared MWA technology targets U.S. benign thyroid nodule treatment following November 2023 clearance
Expert Statements
Haimei Wu, Chairwoman and CEO of Baird Medical
“Securing medical device registrations in Vietnam and advancing through the regulatory process in Egypt are important steps in expanding the presence of our microwave ablation technology in strategic markets beyond the U.S. and PRC”
Haimei Wu, Chairwoman and CEO of Baird Medical
“These developments demonstrate our ability to navigate regulatory requirements across different jurisdictions and expand the reach of our technology across multiple clinical applications, including thyroid nodules and liver tumors.”
Haimei Wu, Chairwoman and CEO of Baird Medical
“At the same time, we are focused on continuing to translate our FDA clearance into accelerating commercial traction in the United States by strengthening our physician relationships and expanding adoption of microwave ablation technology.”
Haimei Wu, Chairwoman and CEO of Baird Medical
“We see strong opportunities to build on our established international presence while establishing a larger foothold in the U.S. market.”
NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a global leader in microwave ablation (MWA) technology, today announced additional medical device registrations in Vietnam and preliminary regulatory approval in Egypt. The preliminary approval in Egypt will help the Company bring its technology to one of the largest markets in the Middle East, while the product registrations in Vietnam will enable Baird to expand the addressable patient population in this key Southeast Asian country. These milestones reflect the continued successful execution of the Company’s international growth and diversification strategy.
In Vietnam, Baird Medical received Class C medical device registration certificates for several products within its microwave ablation portfolio, including its J-series microwave ablation needles for benign thyroid nodules, G-series needles for liver tumors, and MTI-5AT and MTI-5ET microwave ablation generators. The certificates, which follow an initial product registration issued in January 2026, represent an important step in expanding the Company's footprint in Southeast Asia and supporting future commercialization opportunities in the region.
Get started
Create a free account to read the full story.